Develops and commercializes innovative medicines for oncology, autoimmune, and infectious diseases in China.
Zai Lab Limited is a dynamic biopharmaceutical company focused on the development and commercialization of innovative therapies across diverse therapeutic areas such as oncology, autoimmune disorders, infectious diseases, and neuroscience. Operating primarily in Mainland China and Hong Kong, Zai Lab Limited has established a robust portfolio of commercial products and a promising pipeline of investigational drugs. Their current offerings include Zejula, Optune, NUZYRA, and Qinlock, addressing critical medical needs in oncology and infectious diseases.
The company is at the forefront of pioneering treatments like Odronextamab for various lymphomas, Repotrectinib targeting specific mutations in cancer patients, and Margetuximab for breast and gastroesophageal cancers. With a commitment to innovation, Zai Lab Limited also develops advanced therapies such as Adagrasib for KRAS-G12C-mutated cancers, Bemarituzumab for gastric cancers, and a range of investigational compounds like Efgartigimod for autoimmune disorders and KarXT for psychiatric conditions.
Founded in 2013 and headquartered in Shanghai, China, Zai Lab Limited continues to expand its impact through strategic partnerships and a dedicated focus on advancing novel therapies that address unmet medical needs across a spectrum of diseases. The company's innovative approach and extensive pipeline underscore its commitment to improving patient outcomes and shaping the future of healthcare in Asia and beyond.